Journal Watch: aducanumab reduces amyloid aggregates and hints at cognitive benefit in a Phase Ib clinical trial

Written by David Howett, University of Cambridge, UK

On 1 September 2016, Biogen (MA, USA) published the results of their Phase Ib clinical trial in Nature. The double-blind, placebo-controlled study of 165 prodromal and mild Alzheimer’s disease (AD) patients took newspaper headlines by storm and instilled hope for the public and clinical scientists alike. However, whilst the results of this clinical trial are promising, aducanumab is far from a silver bullet for AD. What is aducanumab? Aducanumab is a monoclonal antibody that selectively reacts with insoluble oligomers and insoluble fibrils of amyloid beta (Aβ), but not monomers. Aducanumab was derived from a library of elderly adults with no...

To view this content, please register now for access

It's completely free